Professor John Gribben

Professor John Gribben

MD DSc FRCP FRCPath FMed Sci
Centre: Centre for Haemato-Oncology
Fellowships:
  • Wellcome Trust Clinical Research Fellow 1987-89, UCL
  • Fogarty International Fellowship, 1989-1991, Harvard
Centre Lead, Centre for Haemato-Oncology
This email address is being protected from spambots. You need JavaScript enabled to view it.

QMUL Directory

Cancer Immunotherapy Group

The research interest of my group focuses on immunological approaches to the treatment of haematological cancers.

Research Details

The research interest of my Cancer Immunotherapy Group focuses on immunological approaches to the treatment of haematological cancers. In particular, we are interested in understanding:

  • The molecular mechanisms whereby cancer cells induce changes in the host immune system
  • The use of allogeneic stem cell bone marrow transplant to induce a graft versus leukaemia effect
  • Identification of the antigenic targets expressed by cancer cells
  • Use of agents that will make tumour cells more susceptible to immune cell mediated killing, without impacting on the host immune system

Profile

I hold the Gordon Hamilton Fairley Chair of Medical Oncology at St. Bartholomew's Hospital, Barts Cancer Institute, Queen Mary, University of London. My doctoral studies were performed at University College London as the recipient of a Wellcome Trust Fellowship Award. I continued post-doctoral training with Professor Lee Nadler at the Dana-Farber Cancer Institute, Harvard Medical School.

In 1992, I was appointed to the Faculty at Harvard Medical School, where I remained as Associate Professor of Medicine and an Attending Physician at the Dana-Farber Cancer Institute and Brigham and Women's Hospital, until returning to London in 2005. I am a founding member of the CLL Research Consortium, Associate Editor of Blood and was elected a Fellow of the Academy of Medical Science.

My primary research interests include the immunotherapy of cancer (including stem cell transplantation), the identification of B-cell-tumour antigens; and the detection and treatment of minimal residual disease in leukaemia and lymphoma.

Funding

DateFunding SourceTitle/Amount
2013 Barts And The London Charity BMOU Redevelopment Project
£34,474
2013 Moores Cancer Center,University Of California Chronic Lymphocytic Leukemia Research Consortium
£134,346
2012 Cancer Research UK ECMC Funding
£1,000,000
2012 Barts Health NHS Trust £1,000,000
2012 Barts and The london Charity Improving the allogenic T cell response to tumour using lenalidomibe
£57,140
2012 British Society For Haematology Improving the allogeneic T cell response to tumours
£7,000
2012 Barts And The London Charity Role of immunotherapy using reduced intensity allogeneic stem cell transplants in patients with leukaemia & lymphoma
£15,000
2012 Goldman Sachs International Clinical Research Fellows in Lymphoma funding
£127,380
2012 Nucana Biomed Limited A phase I open label, dose-escalation study to assess the safety, pharmacokinetics and activity of Nuc-1031
£77,974
2012 European Organisation for Research and Treatment of Cancer A phase I study of the EORTC-LG and GIMEMA trial
£19,000
2012 Celgene Corporation The mechanism of action of lenalidomide on malignant and immune cells in chronic
£103,791
2011 Macmillan Cancer Support A Comparison of patient-reported late effects and consequences among patients treated for Hodgkin lymphoma as adults and children
£25,891
2011 Barts And The London Charity Staff Support
£45,351
2011 Barts And The London Charity Barts Cancer Institute Seminar Programme
£50,000
2011 Barts And The london Charity Validation of NOX4 - Salary support
£57,085
2011 Barts And The London Charity The impact of Haematological Cancers on the Immune Microenvironment
£587,957
2011 Barts And The London Charity Integrated genomic and epigenetic studies in Mantle Cell Lymphoma
£150,468
2010 Barts And The London Charity Leukaemia and Lymphoma Samples-Employ Bioinformatics Specialist
£55,000
2010 Immunomedics Inc Phase 2 study combining humanised anti-CD-20 (Veltuzumab), anti CD22 (epratuzumab) or both monocional antibodies with intensive chemotherapy in adults with acute lymphoblastic leukaemia
£40,001
2009 Barts And The London Charity Clinical Research Fellowship
£268,313
  Cancer Research UK Phase 2 study combining humanised anti-CD20 anti-CD22 or both monoclonal antibodies with intensive chemotherapy in adults with recurrent acture lymphoblastic leukaemia
£69,391
2008 CLL Gobal Research Fondation CD3/CD28 in chronic lympocytic leukaemia
£109,612
2008 University Of Nebraska Medical Center Molecular signatures in NHL
£78,267

 

  • NIH Program Grant CLL Research Consortium 2012-2016
  • Baker Foundation Grant 2009-2017

Key Publications

Greaves P, Clear A, Coutinho R, Wilson A, Matthews J, Owen A, Shanyinde M, Lister TA, Calaminici M, Gribben JG. Expression of FOXP3, CD68 and CD20 at Diagnosis in the Microenvironment of Classical Hodgkin Lymphoma is Predictive of outcome. J Clin Oncol, 2013. PMID: 23045593

Gorgun G, Ramsay AG, Holderried TA, Zahrieh D, Le Dieu R, Liu F, Quackenbush J, Croce CM, Gribben JG. E(mu)-TCL1 mice represent a model for immunotherapeutic reversal of chronic lymphocytic leukemia-induced T-cell dysfunction. Proc Natl Acad Sci USA, 2009. PMID: 19332800

Ramsay AG, Johnson AJ, Lee AM, Gorgün G, Le Dieu R, Blum W, Byrd JC, Gribben JG. Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug. J Clin Invest, 2008. PMID: 18551193

Proto-Siqueira R, Panepucci RA, Careta FP, Lee A, Clear A, Morris K, Owen C, Rizzatti EG, Silva WA, Jr., Falcao RP, Zago MA, Gribben JG. SAGE analysis demonstrates increased expression of TOSO contributing to Fas-mediated resistance in CLL. Blood, 2008. PMID: 18434611


Further Publications

For additional publications, please click here.

 


The research interest of my group focuses on immunological approaches to the treatment of haematological cancers.

External Activities

  • EHA Governing Board, 2015-
  • MHRA Haematology Oncology Expert Advisory Panel, 2010-
  • MRC Molecular and Cellular Medicine Board (MCMB), 2007-2012
  • CRUK Clinical Trials Advisory Committee (CTAAC), 2008-2012
  • British Society for Bone Marrow Transplantation Executive Board, 2009-2013
  • Bone Marrow Transplantation Director at Barts, 2004-
  • CRUK Feasibility Study Committee (FSC) 2007-8
  • Leukemia Lymphoma Research Fund Clinical Trials Advisory Panel (CTAP) 2007-2102
  • International Workshop on non-Hodgkin's Lymphoma (iwNHL) Executive Board, 2002-
  • International Workshop on Hodgkin Lymphoma – Programme Committee, 2007-2012
  • NIH – NCI Initial Review Group Subcommittee D 2002-2005
  • Cancer and Leukemia Group B, Correlative Science Committee 2002-2006
  • American Society of Clinical Oncology, Patient communication subcommittee 2002-2004

Editorial Activities

  • Associate Editor, Blood, 2008-

News

This site uses cookies in order to function properly. By continuing to browse, you agree that we can save them on your device. Privacy Policy.